You are here: Home > Yanovski Lab

Physiology, Psychology, and Genetics of Obesity

• Jack A. Yanovski, MD, PhD, Head, Section on Growth and Obesity
• Joo Yun Jun, PhD, Postdoctoral Fellow
• Tusharkumar Patel, PhD, Visiting Fellow
• Miranda Broadney, MD, MPH, Pediatric Endocrine Training Program Fellow
• Sheila M. Brady, RN, FNP, Nurse Practitioner
• Robin Roberson, MS, Technician
• Meghan Byrne, MA, Guest Researcher
• Sarah Russell, MA, Guest Researcher
• Lisa Shank, MA, Guest Researcher
• Elisabeth Davis, BS, Postbaccalaureate Intramural Research Training Award Fellow
• Nejla Ghane, BA, Postbaccalaureate Intramural Research Training Award Fellow
• Anne Claire Grammer, BA, Postbaccalaureate Intramural Research Training Award Fellow
• Noah Levi, BA, Postbaccalaureate Intramural Research Training Award Fellow
• Jordan Levine, BS, Postbaccalaureate Intramural Research Training Award Fellow
• Sarah Mi, BA, Postbaccalaureate Intramural Research Training Award Fellow
• Ginikanwa Onyekaba, BS, Postbaccalaureate Intramural Research Training Award Fellow
• Sophie Ramirez, MS, Postbaccalaureate Intramural Research Training Award Fellow
• Sarah Rubin, BS, Postbaccalaureate Intramural Research Training Award Fellow
• Andrew Uhlman, BS, Postbaccalaureate Intramural Research Training Award Fellow

The prevalence of overweight and obesity in children and adults has tripled during the past 40 years, an alarming rise in body weight that has likely occurred because the current environment affords easy access to calorie-dense foods and requires less voluntary energy expenditure. However, such an environment leads to obesity only in those individuals whose body weight–regulatory systems are not able to control body adiposity with sufficient precision in our high calorie/low activity environment, suggesting that there are subgroups in the U.S. with a uniquely high susceptibility to weight gain under the prevailing environmental conditions. Our primary goal is to elucidate the genetic underpinnings of the metabolic and behavioral endo-phenotypes that contribute to the development of obesity in children. Using our unique longitudinal cohorts of children at risk for adult obesity, who have undergone intensive metabolic and behavioral phenotyping, we examine genetic and phenotypic factors predictive of progression to adult obesity in children who are in the "pre-obese" state, allowing characterization of phenotypes unconfounded by the impact of obesity itself. Once they are identified as linked to obesity, we study intensively genetic variants that impair gene function. We expect that these approaches will improve our ability to predict which children are at greatest risk for obesity and its comorbid conditions and will lead to more targeted, etiology-based prevention and treatment strategies for pediatric obesity.

Genetic factors important for childhood body weight regulation

To identify gene variants affecting body composition, we have been examining polymorphisms in genes involved in the leptin signaling pathway. Genes include the leptin receptor (LEPR), FTO (fat mass and obesity-associated gene), and those encoding proopiomelanocortin (POMC), the melanocortin 3 receptor (MC3R), the melanocortin 4 receptor (MC4R), and brain-derived neurotrophic factor (BDNF). We are currently studying a variant MC3R that is associated with adiposity in children and appears to have functional significance for MC3R signal transduction. Children who were homozygous variant for both C17A and G241A polymorphisms have significantly greater fat mass and higher plasma levels of insulin and leptin than unaffected or heterozygous children and appear to eat more at laboratory test meals (Figure 1). In vitro studies subsequently found that signal transduction and protein expression were significantly lower for the double mutant MC3R. Our ongoing studies attempt to understand the mechanisms by which such sequence alterations may affect body weight. We therefore developed transgenic 'knock-in' mice expressing the human wild-type and human double-mutant MC3R. Using homozygous knock-in mouse models replacing murine Mc3r with wild type human (MC3R^hWT/hWT) and double-mutant (C17A+G241A) human (MC3R^hDM/hDM) MC3R, we found that MC3R^hDM/hDM have greater weight and fat mass (Figure 2), increased energy intake and feeding efficiency, but reduced length and fat-free mass compared with MC3R^hWT/hWT. MC3R^hDM/hDM mice do not have increased adipose-tissue inflammatory-cell infiltration or greater expression of inflammatory markers, despite their greater fat mass. Serum adiponectin is increased in MC3R^hDM/hDM mice and in MC3R^hDM/hDM human subjects (Figure 2). MC3R^hDM/hDM bone- and adipose tissue–derived mesenchymal stem cells (MSCs) differentiate into adipocytes that accumulate more triglyceride than wild-type MC3R^hWT/hWT MSCs. MC3R^hDM/hDM thus impacts nutrient partitioning to generate increased adipose tissue that appears metabolically healthy. The data confirm the importance of MC3R signaling in human metabolism and suggest a previously unrecognized role for the MC3R in adipose tissue development. Ongoing studies continue to improve our understanding of the phenotype of these mice. We are investigating a novel role for the MC3R in the regulation of hepatic autophagy, the role of MC3R in stem cell fate, and how variations in Mc3r may alter signaling of several downstream signaling pathways.

Physiology, metabolism, and psychology of childhood body weight regulation

Our studies are directed at understanding the physiological, psychological, and metabolic factors that place children at risk for undue weight gain. As part of these studies, we examined how best to measure eating-related psychopathology, insulin sensitivity, changes in body composition, energy intake, and energy expenditure in children, and we studied the short- and long-term stability of the components of metabolic syndrome. We found that leptin is an important predictor of weight gain in children: those with high leptin levels gain even more weight when followed longitudinally. We also documented that hyperinsulinemia is positively related to energy intake in non-diabetic, obese children, leading to treatment studies to reduce hyperinsulinemia. We also examined the relationship between depressive symptomatology and insulin resistance in children and adolescents, finding strong associations both cross-sectionally and prospectively between depressive symptoms and insulin resistance independent of body weight. These associations suggest mechanisms whereby insulin resistance may contribute to excessive weight gain in children and have informed some of our treatment approaches to pediatric obesity (described below).

Our evaluations concerning binge-eating behaviors in children suggest that such behaviors also are associated with adiposity in children and abnormalities in metabolism. We found that binge-eating behaviors may predict future weight gain in children at risk for obesity. Thus, children reporting binge-eating behaviors, such as loss of control over eating, gained an average additional 2.4 kg of weight per year compared with children who did not engage in binge eating. Our data also suggest that children endorsing binge eating consume more energy during meals. Actual intake during buffet meals averaged 400 kcal more in children with binge eating, but despite their greater intake, such children reported shorter-lived satiety than children without binge-eating episodes. The ability to consume large quantities of palatable foods, especially when coupled with lower subsequent satiety, may play a role in the greater weight gain found in binge-eating children. Among cohorts of lean and obese youth, we demonstrated that youth with loss of control (LOC) eating had higher serum leptin and were at significantly greater risk for worsening of components of the metabolic syndrome than those without LOC episodes, even after adjusting for adiposity and other relevant covariates. Our data also suggest that anxiety symptoms may interact with LOC eating to become an important co-factor for excessive weight gain among children [Reference 1]. These data also suggest that interventions targeting disordered eating behaviors may potentially be useful in preventing excessive fat gain in children prone to obesity and have led to trials of preventative strategies related to binge eating. Because binge eating appears to be a heritable trait, we also initiated studies to investigate potential genetic factors linked to LOC over-eating.

We study normal weight children and adolescents, children who are already obese, and the non-obese children of obese parents, in order to determine the factors that are most important for the development of complications of obesity in youth. We examine body composition, leptin concentration, metabolic rate, insulin sensitivity, glucose disposal, energy intake at buffet meals, and genetic factors believed to regulate metabolic rate and body composition. We also study psychological and behavioral factors, such as propensity to engage in binge-eating behavior (Figure 3). Children are being followed longitudinally into adulthood. In two protocols, we study actual food consumption of children during meals, to elucidate differences in the calorie and macronutrient content of meals and the circulating hormones related to hunger and satiety in those who either endorse binge-eating behaviors or report no such behaviors. We found that eating in the absence of physiological hunger is a replicable trait that appears linked to obesity. We also investigated the role of sedentary behaviors, such as television watching, as a factor that alters metabolism. In a randomized, controlled, crossover trial (Figure 4), we found that glucose homeostasis was markedly improved in overweight or obese children who engaged in moderate activity for just three minutes every half hour, compared with remaining sedentary [Reference 2]. We hypothesize that differences in these factors will predict the development of obesity in the populations studied and may be of great importance in developing rational approaches for the prevention and treatment of obesity in the diverse U.S. population.

Treatment of obesity and the co-morbid conditions associated with obesity

Given the rapid increase in the prevalence of obesity, the development of treatments for obesity in children and adults is urgently needed, yet current pharmacologic approaches are extremely limited for both children and adults. In several clinical protocols, we have examined approaches for the prevention and treatment of excessive body weight. We completed a randomized controlled trial demonstrating that severely obese adolescents can lose weight when enrolled in a comprehensive weight management program that includes the gastrointestinal lipase inhibitor orlistat as an adjunct to a behavioral modification program. Adolescents treated with orlistat lost significantly more weight, BMI units, and fat mass than controls. We concluded that orlistat added to a behavioral program significantly increased weight loss over a 6-month interval; however, it had little impact on obesity-related co-morbid conditions in obese adolescents. A second obesity treatment study examined the mechanism by which metformin may affect the body weight of younger children who have hyperinsulinemia, and are therefore at risk for later development of type 2 diabetes. Compared with placebo-treated children, in those randomized to metformin BMI, BMI-Z score, and body fat mass declined to a significantly greater extent. Serum glucose and HOMA-IR (homeostatic model assessment of insulin resistance) also declined significantly more in metformin-treated than in placebo-treated children. We recently published studies on the pharmacokinetics of metformin and on how polymorphisms in enzymes affecting metformin clearance impact weight change. Mean population apparent clearance (CL/F) was 68.1 L/h, and mean apparent volume of distribution (V/F) was 28.8 L. Body weight was a covariate of CL/F and V/F. Estimated glomerular filtration rate was a significant covariate of CL/F. The SLC22A1 variant carriers had significantly smaller reductions in percentage of total trunk fat after metformin therapy. The median percentage change in trunk fat was –1.20% (–2.40% to 7.30%) for the SLC22A1 subjects and –2.20% (–9.00% to 0.900%) for those without the variant.

A third study examined prevention of weight gain using interpersonal therapy (IPT) versus a control health education program (HE) in adolescents reporting loss of control eating behaviors [Reference 1]. At 3-year follow-up, baseline social-adjustment problems and trait anxiety moderated outcome. Among girls with high self-reported baseline social-adjustment problems or anxiety, IPT was associated with the steepest declines in BMIz, compared with HE. For adiposity, girls with high or low anxiety in HE and girls with low anxiety in IPT experienced gains, while girls in IPT with high anxiety stabilized. Parent-reports yielded complementary findings. The results have stimulated ongoing research to examine how anxiety may stimulate energy intake. This year, we also published preliminary data from a fourth study examining IPT approaches in younger children, finding good tolerability for such a program. A fifth study examined whether reducing depressive symptoms could ameliorate insulin resistance in adolescents at risk for type 2 diabetes [Reference 3]. Among girls with greater (moderate) baseline depressive symptoms (N = 78), those in cognitive behavioral therapy (CBT) developed lower 2-hr insulin than those in HE. Additional metabolic benefits of CBT were seen for this subgroup between post-treatment analyses and those conducted until the one-year follow-up.

We also participated in a multi-site randomized, placebo-controlled trial of beloranib, a methionyl aminopeptidase 2 inhibitor, to treat the hyperphagia of patients with the Prader-Willi syndrome [Reference 4] (Figure 5). The medication was effective in reducing body weight: compared with placebo, weight change was significantly greater with 1.8 mg (mean difference –8.2%, 95% CI: –10.8 to –5.6) and 2.4 mg beloranib (–9.5%, 95% CI: –12.1 to –6.8). However, the trial had to be stopped because of serious venous thrombotic events in beloranib-treated participants. An ongoing study based on lab data demonstrating attentional biases to high-palatability foods in children with obesity is investigating whether adolescents’ attentional biases can be retrained. We also initiated a translational trial studying the effects of modulating the leptin signaling pathway with the melanocortin agonist setmelanotide in patients with proximal signaling defects, such as PCSK1 insufficiency, and in patients with Bardet Biedl syndrome; the initial data are encouraging. In the coming year, we will also begin another study of specific pharmacotherapy for patients with Prader-Willi syndrome. These latest trials are examples of a precision medicine approach [Reference 5] to treat obesity. Finally, a novel intervention, which has completed enrolment and is currently being analyzed, is a randomized-controlled pilot trial of colchicine to ameliorate the inflammation of obesity and thus improve its complications.

Additional Funding

• Zafgen, Inc: "Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension, Zafgen, Inc.) in Obese Subjects with Prader-Willi Syndrome to Evaluate Total Body Weight, Food-Related Behavior, and Safety over 6 Months." Funds an RCT (random control trial) testing a new methionine aminopeptidase inhibitor in patients with Prader-Willi syndrome and obesity. 2014–2016
• NIH Clinical Center/ORWH "Bench-to-Bedside" Award: Attention Bias Retraining in Adolescents with Loss of Control Eating. 2016–2017
• NIH Clinical Center/ORD "Bench-to-Bedside" Award: Melanocortin agonist to bypass leptin resistance of Bardet-Biedl syndrome. 2017–2018
• Office of Disease Prevention, NIH: Grant supplement to support the clinical protocol "Effects of Interrupting Sedentary Behavior on Metabolic and Cognitive Outcomes in Children." 2016–2017
• Rhythm Pharmaceuticals, Inc: Setmelanotide (RM-493; Rhythm Pharmaceuticals, Inc.) Phase 2 Open-Label Treatment Trials in Patients with Rare Genetic Disorders of Obesity. 2017–2019
• Soleno Therapeutics, Inc. Grant support to fund an RCT testing a diazoxide choline sustained release tablets in patients with Prader-Willi syndrome and hyperphagia. 2018–2020

Publications

1. Tanofsky-Kraff M, Shomaker LB, Wilfley DE, Young JF, Sbrocco T, Stephens M, Brady SM, Galescu O, Demidowich A, Olsen CH, Kozlosky M, Reynolds JC, Yanovski JA. Excess weight gain prevention in adolescents: three-year outcome following a randomized controlled trial. J Consult Clin Psychol 2017;85:218-227.
2. Broadney MM, Belcher BR, Berrigan DA, Brychta RJ, Tigner IL Jr, Shareef F, Papachristopoulou A, Hattenbach JD, Davis EK, Brady SM, Bernstein SB, Courville AB, Drinkard BE, Smith KP, Rosing DR, Wolters PL, Chen KY, Yanovski JA. Effects of interrupting sedentary behavior with short bouts of moderate physical activity on glucose tolerance in children with overweight and obesity: a randomized crossover trial. Diabetes Care 2018;41:2220-2228.
3. Shomaker LB, Kelly NR, Radin RM, Cassidy OL, Shank LM, Brady SM, Demidowich AP, Olsen CH, Chen KY, Stice E, Tanofsky-Kraff M, Yanovski JA. Prevention of insulin resistance in adolescents at risk for type 2 diabetes with depressive symptoms: 1-year follow-up of a randomized trial. Depress Anxiety 2017;34:866-876.
4. McCandless SE, Yanovski JA, Miller J, Fu C, Bird LM, Salehi P, Chan CL, Stafford D, Abuzzahab MJ, Viskochil D, Barlow SE, Angulo M, Myers SE, Whitman BY, Styne D, Roof E, Dykens EM, Scheimann AO, Malloy J, Zhuang D, Taylor K, Hughes TE, Kim DD, Butler MG. Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2017;19:1751-1761.
5. Yanovski SZ, Yanovski JA. Toward precision approaches for the prevention and treatment of obesity. JAMA 2018;319:223-224.

Collaborators

• Silva Arslanian, MD, Children’s Hospital of Pittsburgh, Pittsburgh, PA
• Jeffrey Baron, MD, Section on Growth and Development, NICHD, Bethesda, MD
• Andrew Butler, PhD, The Scripps Research Institute, La Jolla, CA
• Kong Chen, PhD, Clinical Endocrinology Branch, NIDDK, Bethesda, MD
• Anthony Comuzzie, PhD, Southwest National Primate Research Center, San Antonio, TX
• I. Sadaf Farooqi, MD, Cambridge Institute for Medical Research, Cambridge, United Kingdom
• Oksana Gavrilova, PhD, Mouse Metabolism Core Laboratory, NIDDK, Bethesda, MD
• Joan C. Han, MD, Le Bonheur Children’s Hospital, Memphis, TN
• Steven B. Heymsfield, MD, Pennington Biomedical Research Center, Baton Rouge, LA
• Michael Jensen, MD, Mayo Clinic, Rochester, MN
• Rudolph L. Leibel, MD, Columbia University College of Physicians and Surgeons, New York, NY
• Sergey Leikin, PhD, Section on Physical Biochemistry, NICHD, Bethesda, MD
• Cara Olsen, PhD, Uniformed Services University of the Health Sciences, Bethesda, MD
• Vipul Periwal, PhD, Laboratory of Biological Modeling, NIDDK, Bethesda, MD
• Daniel Pine, MD, Section on Development and Affective Neuroscience, NIMH, Bethesda, MD
• Douglas Rosing, MD, Cardiac Consultation Service, NHLBI, Bethesda, MD
• Peter J. Schmidt, MD, Section on Behavioral Endocrinology, NIMH, Bethesda, MD
• Lauren B. Shomaker, PhD, University of Colorado, Boulder, CO
• Eric Stice, PhD, Oregon Research Institute, Eugene, OR
• Marian Tanofsky-Kraff, PhD, Uniformed Services University of the Health Sciences, Bethesda, MD
• B. Timothy Walsh, PhD, Columbia University College of Physicians and Surgeons, New York, NY
• Denise E. Wilfley, PhD, Washington University School of Medicine, St. Louis, MO
• Joshua Zimmerberg, MD, PhD, Section on Integrative Biophysics, NICHD, Bethesda, MD

Contact

For more information, email yanovskj@mail.nih.gov or visit http://sgo.nichd.nih.gov.

Top of Page